Evidence map›Paper›PMID 40098720›Full record

ArticleInternational journal of nanomedicine2025

Inhibition of Ovarian Cancer Growth, Metastasis and Reverse the Tumor Microenvironment by Dual Drug-Loaded Polymer Micelle Targeting Tumor Microenvironment.

Lu Zhang, Ruibo Guo, Muhan Chen, Mo Liu, Yang Liu, Yang Yu, Juan Zang, Liang Kong, Xuetao Li

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Stimuli-responsive bioengineered platforms for precision cancer therapy.Frontiers in bioengineering and biotechnology · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lu ZhangSchool of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, People's Republic of China.
Ruibo GuoSchool of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, People's Republic of China.
Muhan ChenSchool of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, People's Republic of China.
Mo LiuSchool of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, People's Republic of China.
Yang LiuSchool of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, People's Republic of China.
Yang YuSchool of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, People's Republic of China.
Juan ZangSchool of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, People's Republic of China.
Liang Kong *School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, People's Republic of China.
Xuetao Li *School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ovarian cancer is a malignant tumor that arises in the female reproductive system and is associated with a very high mortality rate. This is primarily due to the highly invasive nature of metastasis and recurrence. Transforming the immune environment from an immunosuppressive state to an anti-tumor state through the phenotypic transformation of tumor-associated macrophages is crucial for inhibiting the growth, metastasis, and recurrence of ovarian cancer. Methods: A polymer micelle (RC-PH-Ms) containing paclitaxel (PTX) and honokiol (HNK) was designed based on high expression of reactive oxygen species in the tumor microenvironment. Once the micelles are actively targeted to the tumor microenvironment characterized by elevated levels of reactive oxygen species, the responsive bond is cleaved, thereby exposing the secondary targeting ligand C7R. The released PTX and HNK facilitate the transformation of relevant macrophages in the tumor microenvironment from an M2 phenotype to an M1 phenotype, which in turn inhibits tumor growth, invasion and metastasis, inhibit angiogenesis and reduce tumor recurrence. Results: The effects of RC-PH-Ms on modulating the immune microenvironment and inhibiting tumor growth, invasion and metastasis, vascularization and recurrence were investigated both in vivo and in vitro. Conclusion: RC-PH-Ms can significantly inhibit the metastasis and recurrence of ovarian cancer, which provides a new perspective for clinical treatment.

Indexed as

Biphenyl CompoundsLignansOvarian NeoplasmsPaclitaxelTumor MicroenvironmentAllyl CompoundsAnimalsCell Line, TumorDrug CarriersFemaleHumansMiceMice, Inbred BALB CMicellesNeoplasm MetastasisPhenolsAllyl CompoundsBiphenyl CompoundsDrug CarriershonokiolLignansMicellesPaclitaxelPhenolsPolymersReactive Oxygen Speciesimmunotherapyovarian cancerpolymer micellerecrudescencetumor metastasis

Identifiers

PMID40098720
PMCPMC11911825

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.